525: Elexacaftor/tezacaftor/ivacaftor therapy alters the CF lung mucus metabolome, reshaping microbiome niche space
Robert A. Quinn(Michigan State University), Douglas Conrad(UC San Diego Health System), Douglas V. Guzior(DiscoveryBioMed (United States)), Kerri A. Neugebauer(Michigan State University), Alicia Castillo-Bahena(Spectrum Health), Rajesh Thomas, Jenna Mielke(University of California, San Diego), Marc McClelland(Spectrum Health), Lauren M. Sosinski, Lydia-Ann J. Ghuneim(Michigan State University)
Cited by 1
Related Papers
Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking
|Nature Biotechnology|2016|4.6k
Feature-based molecular networking in the GNPS analysis environment
|Nature Methods|2020|1.5k
Review: microbial transformations of human bile acids
|Microbiome|2021|712
Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity
|Nature Microbiology|2022|385
COPDGene® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease
|Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation|2019|181